Animal Models for Medication Development and Application to Treat Fetal Alcohol Effects

S. Barron; A. Hawkey; L. Fields; J. M. Littleton

doi:10.1016/bs.irn.2016.02.002

Animal Models for Medication Development and Application to Treat Fetal Alcohol Effects

S. Barron, A. Hawkey, L. Fields, J. M. Littleton

Psychology

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

9 Scopus citations

Abstract

Ethanol consumption during pregnancy can have lifelong consequences for the offspring, their family and society. Fetal alcohol spectrum disorders (FASD) include a range of physical and behavioral effects with the most significant impact occurring as a result of the effects of ethanol on the developing central nervous system (CNS). To date, there are no FDA approved drugs that have been tested that prevent/reduce or specifically treat the symptoms of FASD. There are several promising lines of research from rodent models aimed at reducing the neurotoxic effects of ethanol on the developing CNS or in treating the resulting behavioral impairments but these have not yet moved to clinical testing. The current review discusses some of the most promising targets for intervention and provides a review of the past and ongoing efforts to develop and screen pharmacological treatments for reducing the effects of prenatal ethanol exposure.

Original language	English
Title of host publication	International Review of Neurobiology
Pages	423-440
Number of pages	18
DOIs	https://doi.org/10.1016/bs.irn.2016.02.002
State	Published - 2016

Publication series

Name	International Review of Neurobiology
Volume	126
ISSN (Print)	0074-7742
ISSN (Electronic)	2162-5514

Bibliographical note

Funding Information:
This work was funded, in part, by SBIR AA021038 and a NIAAA contract to JML and a Research Grant from the Vice President for Research at University of Kentucky to SB.

Publisher Copyright:
© 2016 Elsevier Inc.

Keywords

Fetal alcohol spectrum disorders
Novel flavonoids
Polyamine modulators
Rodent models
α7 Agonists

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1016/bs.irn.2016.02.002

Cite this

@inbook{b0feb9b514b24f60b1a6c17d3180c7e4,

title = "Animal Models for Medication Development and Application to Treat Fetal Alcohol Effects",

abstract = "Ethanol consumption during pregnancy can have lifelong consequences for the offspring, their family and society. Fetal alcohol spectrum disorders (FASD) include a range of physical and behavioral effects with the most significant impact occurring as a result of the effects of ethanol on the developing central nervous system (CNS). To date, there are no FDA approved drugs that have been tested that prevent/reduce or specifically treat the symptoms of FASD. There are several promising lines of research from rodent models aimed at reducing the neurotoxic effects of ethanol on the developing CNS or in treating the resulting behavioral impairments but these have not yet moved to clinical testing. The current review discusses some of the most promising targets for intervention and provides a review of the past and ongoing efforts to develop and screen pharmacological treatments for reducing the effects of prenatal ethanol exposure.",

keywords = "Fetal alcohol spectrum disorders, Novel flavonoids, Polyamine modulators, Rodent models, α7 Agonists",

author = "S. Barron and A. Hawkey and L. Fields and Littleton, {J. M.}",

note = "Funding Information: This work was funded, in part, by SBIR AA021038 and a NIAAA contract to JML and a Research Grant from the Vice President for Research at University of Kentucky to SB. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

doi = "10.1016/bs.irn.2016.02.002",

language = "English",

series = "International Review of Neurobiology",

pages = "423--440",

booktitle = "International Review of Neurobiology",

}

TY - CHAP

T1 - Animal Models for Medication Development and Application to Treat Fetal Alcohol Effects

AU - Barron, S.

AU - Hawkey, A.

AU - Fields, L.

AU - Littleton, J. M.

N1 - Funding Information: This work was funded, in part, by SBIR AA021038 and a NIAAA contract to JML and a Research Grant from the Vice President for Research at University of Kentucky to SB. Publisher Copyright: © 2016 Elsevier Inc.

PY - 2016

Y1 - 2016

N2 - Ethanol consumption during pregnancy can have lifelong consequences for the offspring, their family and society. Fetal alcohol spectrum disorders (FASD) include a range of physical and behavioral effects with the most significant impact occurring as a result of the effects of ethanol on the developing central nervous system (CNS). To date, there are no FDA approved drugs that have been tested that prevent/reduce or specifically treat the symptoms of FASD. There are several promising lines of research from rodent models aimed at reducing the neurotoxic effects of ethanol on the developing CNS or in treating the resulting behavioral impairments but these have not yet moved to clinical testing. The current review discusses some of the most promising targets for intervention and provides a review of the past and ongoing efforts to develop and screen pharmacological treatments for reducing the effects of prenatal ethanol exposure.

AB - Ethanol consumption during pregnancy can have lifelong consequences for the offspring, their family and society. Fetal alcohol spectrum disorders (FASD) include a range of physical and behavioral effects with the most significant impact occurring as a result of the effects of ethanol on the developing central nervous system (CNS). To date, there are no FDA approved drugs that have been tested that prevent/reduce or specifically treat the symptoms of FASD. There are several promising lines of research from rodent models aimed at reducing the neurotoxic effects of ethanol on the developing CNS or in treating the resulting behavioral impairments but these have not yet moved to clinical testing. The current review discusses some of the most promising targets for intervention and provides a review of the past and ongoing efforts to develop and screen pharmacological treatments for reducing the effects of prenatal ethanol exposure.

KW - Fetal alcohol spectrum disorders

KW - Novel flavonoids

KW - Polyamine modulators

KW - Rodent models

KW - α7 Agonists

UR - http://www.scopus.com/inward/record.url?scp=84959258799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959258799&partnerID=8YFLogxK

U2 - 10.1016/bs.irn.2016.02.002

DO - 10.1016/bs.irn.2016.02.002

M3 - Chapter

C2 - 27055621

AN - SCOPUS:84959258799

T3 - International Review of Neurobiology

SP - 423

EP - 440

BT - International Review of Neurobiology

ER -

Animal Models for Medication Development and Application to Treat Fetal Alcohol Effects

Abstract

Publication series

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this